Table 2.
Demographics for the discovery cohort for proteomics analysis
| Plaque disruption | No plaque disruption | |
|---|---|---|
| Number (male) | 10 (7) | 10 (5) |
| Age [years (SD)] | 66 (8) | 67 (12) |
| Acute coronary syndrome [n (%)] | 5 (50) | 6 (60) |
| Smoking status [n (%)] | ||
| Current smoker | 1 (10) | 1 (10) |
| Past history of smoking (>1 month) | 7 (70) | 4 (40) |
| Never smoked | 2 (20) | 5 (50) |
| Past History of IHD [n (%)] | ||
| MI/ACS | 2 (20) | 5 (50) |
| Stable angina | 4 (40) | 0 (0) |
| Hypertension [n (%)] | 6 (60) | 8 (80) |
| Hypercholesterolemia [n (%)] | 8 (80) | 6 (60) |
| Diabetes mellitus [n (%)] | 0 (0) | 0 (0) |
| Family history of IHD [n (%)] | 6 (60) | 5 (50) |
| Regular medication [n (%)] | ||
| Aspirin | 6 (60) | 8 (80) |
| Thienopyridine | 3 (30) | 4 (30) |
| Statin | 7 (70) | 9 (70) |
| β-blocker | 5 (50) | 6 (50) |
| ACE inhibitor/ARB | 6 (60) | 7 (60) |
| Plasma lipid profile | ||
| Total cholesterol [mmol/L (SD)] | 3.7 (0.4) | 3.8 (1.39) |
| HDL [mmol/L (SD)] | 1.0 (0.3) | 0.9 (0.3) |
| LDL [mmol/L (SD)] | 2.0 (0.3) | 2.3 (1.0) |
| Triglyceride [mmol/L (SD)] | 1.5 (0.7) | 1.5 (0.6) |